US EditionPublished • loading... • Updated
Vivani to initiate study of GLP-1 implant in 2026
Summary by Drug Delivery Business
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Vivani to initiate study of GLP-1 implant in 2026
The Vivani NanoPortal technology. [Image courtesy of Vivani]Vivani Medical (Nasdaq:VANI) today announced third-quarter earnings results that included timeline updates on its semaglutide implant. The Alameda, California-based company develops NanoPortal technology, which steadily delivers medication over extended periods of time. Vivani aims to guarantee correct patient doses while avoiding potential safety concerns around fluctuating drug releas…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
